Skip to main content

Table 7 Statistical analyses of overall survival

From: Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival

 

Overall survival

HR

95% confidence interval

p value

Univariate analysis

 Demographic

  Sex (male vs female)

0.887

0.396–1.987

0.770

  Age (< 60 vs 60+)

1.461

0.625–3.414

0.381

 Cytogenetic/clinical factors

  Risk groups (favorable vs intermediate vs adverse)

2.325

1.183–4.569

0.014

  FLT3 (WT vs mutated)

1.282

0.474–3.466

0.624

  Response (NR vs CR)

0.213

0.089–0.509

0.001

  WBC count (low vs high)

1.168

0.514–2.650

0.711

  LDH level (low vs high)

0.242

0.101–0.584

0.002

 Methylation

  CG6 (low vs high)

0.894

0.386–2.068

0.793

  CG7 (low vs high)

0.380

0.157–0.917

0.031

  CG8 (low vs high)

0.762

0.335–1.731

0.516

  CG9 (low vs high)

0.331

0.136–0.805

0.015

 Expression

  DLK1 (low vs high)

3.212

1.096–9.413

0.033

  MEG3 (low vs high)

2.294

0.819–6.421

0.114

  DLK1/MEG3 (low vs high)

0.668

0.247–1.808

0.428

Multivariate analysis

 Methylation

  CG7 (low vs high)

0.533

0.185–1.538

0.245

  CG9 (low vs high)

0.294

0.092–0.935

0.038

 Expression

  DLK1 (low vs high)

1.758

0.467–6.615

0.404

  1. Low or high refers to values either lower or higher than median calculated for all AML patients included in this study. HR hazard rate, FLT3 FMS-like tyrosine kinase 3, NR non-responders, CR complete remission